179 related articles for article (PubMed ID: 15542633)
1. Conventional protein kinase C inhibition prevents alpha interferon-mediated hepatitis C virus replicon clearance by impairing STAT activation.
Fimia GM; Evangelisti C; Alonzi T; Romani M; Fratini F; Paonessa G; Ippolito G; Tripodi M; Piacentini M
J Virol; 2004 Dec; 78(23):12809-16. PubMed ID: 15542633
[TBL] [Abstract][Full Text] [Related]
2. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line.
Zhu H; Zhao H; Collins CD; Eckenrode SE; Run Q; McIndoe RA; Crawford JM; Nelson DR; She JX; Liu C
Hepatology; 2003 May; 37(5):1180-8. PubMed ID: 12717400
[TBL] [Abstract][Full Text] [Related]
3. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene.
Basu A; Meyer K; Ray RB; Ray R
Virology; 2001 Sep; 288(2):379-90. PubMed ID: 11601909
[TBL] [Abstract][Full Text] [Related]
5. STAT3 induces anti-hepatitis C viral activity in liver cells.
Zhu H; Shang X; Terada N; Liu C
Biochem Biophys Res Commun; 2004 Nov; 324(2):518-28. PubMed ID: 15474458
[TBL] [Abstract][Full Text] [Related]
6. Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Plumlee CR; Lazaro CA; Fausto N; Polyak SJ
Virol J; 2005 Dec; 2():89. PubMed ID: 16324217
[TBL] [Abstract][Full Text] [Related]
7. Involvement of p38 signaling pathway in interferon-alpha-mediated antiviral activity toward hepatitis C virus.
Ishida H; Ohkawa K; Hosui A; Hiramatsu N; Kanto T; Ueda K; Takehara T; Hayashi N
Biochem Biophys Res Commun; 2004 Aug; 321(3):722-7. PubMed ID: 15358166
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells inhibit hepatitis C virus expression.
Li Y; Zhang T; Ho C; Orange JS; Douglas SD; Ho WZ
J Leukoc Biol; 2004 Dec; 76(6):1171-9. PubMed ID: 15339939
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
[TBL] [Abstract][Full Text] [Related]
10. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies.
Larrea E; Aldabe R; Molano E; Fernandez-Rodriguez CM; Ametzazurra A; Civeira MP; Prieto J
Gut; 2006 Aug; 55(8):1188-96. PubMed ID: 16120756
[TBL] [Abstract][Full Text] [Related]
11. Identification of the nonstructural protein 4B of hepatitis C virus as a factor that inhibits the antiviral activity of interferon-alpha.
Xu J; Liu S; Xu Y; Tien P; Gao G
Virus Res; 2009 Apr; 141(1):55-62. PubMed ID: 19185598
[TBL] [Abstract][Full Text] [Related]
12. [Investigating the inhibitory effects of interferon-alpha on the replication of hepatitis C virus replicon].
Jia YT; Wei L; Jiang D; Cong X; Fei R
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2065-9. PubMed ID: 16313804
[TBL] [Abstract][Full Text] [Related]
13. Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.
Liu WL; Su WC; Cheng CW; Hwang LH; Wang CC; Chen HL; Chen DS; Lai MY
J Infect Dis; 2007 Aug; 196(3):425-34. PubMed ID: 17597457
[TBL] [Abstract][Full Text] [Related]
14. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells.
Malcolm BA; Liu R; Lahser F; Agrawal S; Belanger B; Butkiewicz N; Chase R; Gheyas F; Hart A; Hesk D; Ingravallo P; Jiang C; Kong R; Lu J; Pichardo J; Prongay A; Skelton A; Tong X; Venkatraman S; Xia E; Girijavallabhan V; Njoroge FG
Antimicrob Agents Chemother; 2006 Mar; 50(3):1013-20. PubMed ID: 16495264
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo.
Pan Q; de Ruiter PE; Metselaar HJ; Kwekkeboom J; de Jonge J; Tilanus HW; Janssen HL; van der Laan LJ
Hepatology; 2012 Jun; 55(6):1673-83. PubMed ID: 22213147
[TBL] [Abstract][Full Text] [Related]
16. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1.
Taylor DR; Puig M; Darnell ME; Mihalik K; Feinstone SM
J Virol; 2005 May; 79(10):6291-8. PubMed ID: 15858013
[TBL] [Abstract][Full Text] [Related]
17. Double-stranded RNA-activated protein kinase inhibits hepatitis C virus replication but may be not essential in interferon treatment.
Chang JH; Kato N; Muroyama R; Taniguchi H; Guleng B; Dharel N; Shao RX; Tateishi K; Jazag A; Kawabe T; Omata M
Liver Int; 2010 Feb; 30(2):311-8. PubMed ID: 19840259
[TBL] [Abstract][Full Text] [Related]
18. Interference with ERK and STAT signaling pathways and inhibition of hepatitis C virus replication by ribavirin.
Zhao LJ; Wang W; Liu Y; Ren H; Qi ZT
Antiviral Res; 2012 Nov; 96(2):260-8. PubMed ID: 22985631
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon.
Hazari S; Taylor L; Haque S; Garry RF; Florman S; Luftig R; Regenstein F; Dash S
Virol J; 2007 Sep; 4():89. PubMed ID: 17877826
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
